Chronic kidney disease (CKD) stage 3 is characterized by reduced exercise capacity, muscle weakness, and increased cardiovascular risk, which negatively impact quality of life. Exercise interventions have shown benefits in improving functional outcomes, but traditional aerobic training may be limited due to comorbidities and reduced physiological reserve. Intermittent hypoxic training (IHT) improves oxygen utilization, cardiovascular adaptation, and mitochondrial function. Specialized hypoxicator devices are costly and not widely available, so practical alternatives such as hypoventilation training and breathing restriction masks may provide comparable benefits.
Study Objective:
To evaluate the effects of hypoventilation training and breathing restriction mask training on exercise tolerance, cardiovascular function, kidney function, fatigue, and quality of life in CKD stage 3 patients.
Study Design:
Randomized controlled trial including 60 patients with CKD stage 3, aged 40-65 years, recruited from outpatient clinics at Aboker Hospital and Pharos University. Participants will be screened for eligibility through medical history, vital signs, and laboratory tests (serum creatinine, eGFR, hemoglobin, electrolytes).
Interventions:
Group A - Hypoventilation Training:
Moderate-intensity aerobic exercise on a cycle ergometer (40-60% HR reserve)
Intermittent breath-holding: 5-10 seconds every 1-2 minutes
Continuous monitoring of SpO₂, heart rate, and blood pressure
Group B - Breathing Restriction Mask Training:
Same aerobic protocol as Group A
Participants wear an adjustable resistance mask to simulate hypoxia
Mask set to induce mild hypoxemia (SpO₂ ≥85%)
Continuous monitoring of SpO₂, heart rate, and blood pressure
Group C - Control Group:
Same aerobic exercise protocol under normal breathing conditions
Moderate intensity (40-60% HR reserve)
Periodic monitoring of vital signs for safety
Intervention Duration:
12 weeks, 3 supervised sessions per week, 30 minutes per session
Outcome Measures:
Primary Outcome:
Exercise tolerance assessed via 6-Minute Walk Test (6MWT) at baseline and post-intervention
Secondary Outcomes:
Fatigue: Fatigue Severity Scale (FSS), self-reported, 9 items, 7-point Likert scale
Quality of Life: KDQOL-36, disease-specific questionnaire covering physical/mental health, symptoms, effects, and burden of CKD
Cardiovascular Assessment: Blood pressure (SBP, DBP) and Heart Rate Recovery (HRR = HR\_peak - HR\_1min)
Kidney Function: Serum creatinine and eGFR (CKD-EPI/MDRD
